Mon Sep 23 23:09:46 UTC 2024: ## 23andMe Faces Uncertainty as Board Resigns Amidst Financial Woes

Direct-to-consumer (DTC) genetic testing pioneer 23andMe, once hailed as the “2008 Invention of the Year” by Time Magazine, is facing turbulent times. This week, the company’s entire board of directors, except for founder Anne Wojcicki, resigned following her plans to take the company private again.

23andMe went public in 2021 but has yet to turn a profit, with the Wall Street Journal reporting that it will run out of cash next year. Despite these financial challenges, a potential buyer has emerged, according to a post on the DNA-Newbie list.

While 23andMe remains a popular choice for exploring health-related genes, it has lost its lead in the genealogy market to Ancestry.com, which now boasts more than double the user base. This is largely attributed to 23andMe’s one-time sale model, which contrasts with Ancestry and MyHeritage’s subscription-based genealogy databases.

The company’s struggles can be traced back to several factors, including a data breach in 2022 that led to a class action lawsuit and the removal of popular features like the chromosome browser. Furthermore, while 23andMe has been successful in leveraging its vast database for research, discovering potential health issues doesn’t seem to be a strong motivator for most consumers, who are more interested in exploring their ethnic roots.

Despite the uncertainty surrounding its future, 23andMe has made significant contributions to the field of genetics, including identifying genetic associations with Parkinson’s, preterm birth, and other medical conditions. Users are advised to download their raw DNA data and consider transferring it to other platforms for analysis.

While some users are concerned about the company’s future, others remain optimistic that a new buyer will emerge and ensure 23andMe’s continued success.

Read More